Ibio Inc (IBIO)
NASDAQ:IBIO
Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$2.06
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.06
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $3.82
Previous CloseN/A
Volume55.53K
Average Volume (3M)897.76K
Market Cap
$58.55M
Enterprise Value-$643.05K
Total Cash (Recent Filing)$52.70M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding36,143,562
10 Day Avg. Volume614,400
30 Day Avg. Volume897,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap-0.01
Enterprise Value/Revenue-2.14
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$5.50Price Target Upside166.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$180.00K
Bulls Say, Bears Say
Bulls Say
Product DifferentiationAn engineered long half-life for IBIO-600 that could allow infrequent dosing offers a potential convenience and adherence advantage versus more frequent injectable metabolic therapies.
Regulatory ProgressRegulatory clearance to start a Phase 1 study of IBIO-600 in Australia advances first-in-human testing and moves the company closer to clinical proof of concept for its long-acting myostatin/GDF11 antibody.
Target ValidationHuman genetic evidence linking activin E inhibition to improved body composition supports IBIO-610's biological rationale and strengthens the case for its obesity-focused development strategy.
Bears Say
Development Stage RiskPrograms remain preclinical, so company value is highly contingent on upcoming first-in-human data and competitor clinical readouts, creating heightened execution risk.
Financing RiskLimited cash runway and ongoing cash burn present a financing risk that may require additional capital, which could dilute shareholders or pressure program timelines.
Market SentimentElevated short interest combined with weakened investor sentiment after disappointing WVE-007 results increases downside pressure on the stock and may amplify share volatility.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $58.55M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is May 18, 2026 which is in 18 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Feb 10, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.05.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 36,143,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -2.643%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (166.99% Upside)
$5.50 (166.99% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $97.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.72%
12-Months-Change
Fundamentals
Return on Equity
-71.26%
Trailing 12-Months
Asset Growth
196.78%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.50
▲(166.99% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.84% Insiders
2.64% Mutual Funds
0.06% Other Institutional Investors
93.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---